SIGA Technologies (SIGA)

SIGA’s business is closely tied to national preparedness programs rather than traditional consumer or hospital drug demand. The company sells oral TPOXX to the US government and to international governments or government-affiliated buyers that stockpile treatments for potential outbreaks or biological threats. It also supports intravenous TPOXX, which provides an option for patients who cannot take an oral formulation. This focus gives SIGA a distinctive profile within the biotechnology and pharmaceutical sector, as revenue can be driven by procurement contracts, replenishment orders, and emergency-response planning.

The company operates as a single reporting segment covering TPOXX sales and related research and development services. Its work sits at the intersection of antiviral science, public health policy, and government contracting. Investors typically view SIGA through the lens of contract visibility, regulatory developments, global demand for orthopoxvirus treatments, and the durability of government stockpiling programs. While narrower than diversified pharmaceutical peers, SIGA has a specialized position built around a product with strategic importance for health security.